Takeda formally completes Shire acquisition

Japan’s Takeda Pharmaceutical (TYO: 4502) has announced the formal completion of its $62 billion acquisition of the rare disease specialist Shire.

Operating in around 80 countries or regions, the newly-formed entity will have global revenues of over $30 billion, and will focus on four main therapeutic areas - oncology, gastroenterology, neuroscience and rare diseases.

Chief executive Christophe Weber said he was “pleased to have completed the acquisition several months earlier than expected,” adding that the company seeks to deliver “highly-innovative medicines to patients around the world with expanded scale and geographical footprint.”